Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oncopeptides AB (publ)
  6. Summary
    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
8.655(c) 8.045(c) 8.07(c) 8.35(c) 7.94(c) Last
1 877 933 1 571 863 1 979 073 1 682 616 1 439 726 Volume
-1.65% -7.05% +0.31% +3.47% -4.91% Change
More quotes
Estimated financial data (e)
Sales 2021 156 M 17,0 M 17,0 M
Net income 2021 -1 302 M -142 M -142 M
Net cash position 2021 187 M 20,3 M 20,3 M
P/E ratio 2021 -0,44x
Yield 2021 -
Sales 2022 8,17 M 0,89 M 0,89 M
Net income 2022 -393 M -42,7 M -42,7 M
Net cash position 2022 75,4 M 8,20 M 8,20 M
P/E ratio 2022 -1,89x
Yield 2022 -
Capitalization 598 M 65,1 M 65,0 M
EV / Sales 2021 2,63x
EV / Sales 2022 64,0x
Nbr of Employees 321
Free-Float -
More Financials
Company
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The CompanyÔÇÖs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company... 
Sector
Biotechnology & Medical Research
Calendar
01/24 | 03:00amSpecial Situation
More about the company
Ratings of Oncopeptides AB (publ)
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about ONCOPEPTIDES AB (PUBL)
01/21ONCOPEPTIDES : Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto
PU
01/21Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market i..
AQ
01/21Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Mar..
CI
01/13Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
AQ
01/13Oncopeptides AB Announces Data from Phase 3 Ocean Study Published in the Lancet Haemato..
CI
01/05Oncopeptides announces year-end cash 2021
AQ
2021Multiple Myeloma Hub continues to provide the latest treatment and research updates in ..
AQ
2021Oncopeptides presents new melflufen data at the Annual American Society of Hematology M..
AQ
2021Oncopeptides publishes Q3 2021 report
AQ
2021Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
2021ONCOPEPTIDES : Webcast - Presentation of the Q3 Interim Report 2021
PU
2021Invitation to presentation of the Q3 2021 results
AQ
2021Oncopeptides Jumps 39% as New CEO Takes Over
MT
2021Jakob Lindberg appointed CEO of Oncopeptides
AQ
2021Oncopeptides AB Announces Changes in CEO
CI
More news
News in other languages on ONCOPEPTIDES AB (PUBL)
01/21Oncopeptides annule le retrait volontaire de Pepaxto aux États-Unis Aucune intention de..
01/13Oncopeptides AB (Publ) annonce que les données de l'étude de phase 3 Ocean ont été publ..
2021OPINIONES DE LOS ANALISTAS DEL DÍA : AXA, Bayer, Merck, Nordex, Subsea, Geberit, Biontech,..
2021Coronavirus vs. Black Friday
2021Coronavirus vs. Black Friday
More news
Chart ONCOPEPTIDES AB (PUBL)
Duration : Period :
Oncopeptides AB (publ) Technical Analysis Chart | ONCO | SE0009414576 | MarketScreener
Technical analysis trends ONCOPEPTIDES AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 7,94 SEK
Average target price 5,35 SEK
Spread / Average Target -32,6%
EPS Revisions
Managers and Directors
Stig Anders Jakob Lindberg Chief Executive & Scientific Officer
Annika Muskantor Chief Financial Officer
Per Wold-Olsen Chairman
Fredrik Lehmann Head-Research, Chemistry, Manufacturing & Control
Klaas Bakker Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ONCOPEPTIDES AB (PUBL)-5.48%65
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624